Hyperium (Rilmenidine Dihydrogen Phosphate)

Rilmenidine selectively stimulates central imidazoline I1 receptors. This action decreases sympathetic nervous system activity, leading to reduced peripheral vascular resistance and consequently lower blood pressure.

The dose of Hyperium is individualized by a qualified prescriber based on the patient’s blood pressure, renal function, and overall clinical condition. Patients should follow the exact regimen provided by their healthcare professional.

Safety of rilmenidine in pregnancy or lactation has not been fully established. It should only be used if the potential benefit justifies the possible risk to the fetus or infant, and only under medical supervision.

To request Hyperium, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike ACE inhibitors or beta‑blockers, rilmenidine acts on imidazoline I1 receptors, offering an alternative mechanism. It may be preferred for patients who experience side effects from other classes or need an additional agent to achieve target blood pressure.

Hyperium should be stored at room temperature, below 25 °C, in its original packaging. Keep it away from moisture, heat and direct sunlight to maintain product stability.

Hyperium is taken orally, usually with a glass of water. The tablet should be swallowed whole and not chewed or crushed unless specifically instructed by a healthcare professional.

Serious adverse events, although rare, include severe hypotension, bradycardia and significant liver enzyme elevations. Patients should seek immediate medical attention if they experience fainting, rapid heartbeat, or signs of liver dysfunction such as jaundice.

Hyperium is contraindicated in patients with known hypersensitivity to rilmenidine or any component of the formulation, and in those with severe hypotension or uncontrolled heart failure. Clinicians should also evaluate suitability in patients with significant renal or hepatic impairment.